Patents Examined by Robert D. Budens
  • Patent number: 6515110
    Abstract: Compositions of, genetic constructions coding for, and methods for producing multivalent antigen-binding proteins are described and claimed. The methods include purification of compositions containing both monomeric and multivalent forms of single polypeptide chain molecules, and production of multivalent proteins from purified monomers. Production of multivalent proteins may occur by a concentration-dependent association of monomeric proteins, or by rearrangement of regions involving dissociation followed by reassociation of different regions. Bivalent proteins, including homobivalent and heterobivalent proteins, are made in the present invention. Genetic sequences coding for bivalent single-chain antigen-binding proteins are disclosed. Uses include all those appropriate for monoclonal and polyclonal antibodies and fragments thereof, including use as a bispecific antigen-binding molecule.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: February 4, 2003
    Assignee: Enzon, Inc.
    Inventors: Marc D. Whitlow, James F. Wood, Karl D. Hardman, Robert E. Bird, David Filpula, Michele Rollence
  • Patent number: 6475718
    Abstract: The orphan seven transmembrane domain receptor, APJ, can function as a coreceptor for cellular infection by the HIV virus. The establishment of cell lines that coexpress CD4 and APJ provide valuable tools for continuing research on HIV infection and the development of anti-HIV therapeutics.
    Type: Grant
    Filed: September 8, 1998
    Date of Patent: November 5, 2002
    Assignees: Schering Aktiengesellschaft, The Trustees of the University of Pennsylvania
    Inventors: Robert W. Doms, Daryl Faulds, Joseph E. Hesselgesser, Richard Horuk, Branislava Mitrovic, Yiqing Zhou
  • Patent number: 6399294
    Abstract: An HIV-1 type (or subtype) O retrovirus protein, or a natural or synthetic polypeptide or peptide including at least a part of said protein, which is capable of being recognised by antibodies isolated from a serum resulting from infection by an HIV-1 type O VAU strain or an HIV-1 type (or subtype) O DUR strain.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: June 4, 2002
    Assignee: Institut Pasteur
    Inventors: Pierre Charneau, Fran├žois Clavel, Andrew Borman, Caroline Quillent, Denise Guetard, Luc Montagnier, Jacqueline Donjon De Saint-Martin, Jacques Cohen
  • Patent number: 6383765
    Abstract: An isolated envelope polypeptide of Feline Immunodeficiency Virus (FIV) that reacts specifically with a gp-130 envelope specific monoclonal antibody. Immunoassays using such isolated polypeptides are also disclosed.
    Type: Grant
    Filed: May 6, 1997
    Date of Patent: May 7, 2002
    Assignee: Idexx Corporation
    Inventors: Philip R. Andersen, Thomas P. O'Connor, Quentin J. Tonelli
  • Patent number: 6344545
    Abstract: This invention provides methods for inhibiting fusion of HIV-1 to CD4+ cells which comprise contacting CD4+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4+ cells is inhibited. This invention also provides methods for inhibiting HIV-1 infection of CD4+ cells which comprise contacting CD4+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4+ cells is inhibited, thereby inhibiting the HIV-1 infection. This invention provides non-chemokine agents capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4+ cells.
    Type: Grant
    Filed: April 2, 1997
    Date of Patent: February 5, 2002
    Assignee: Progenics Pharmaceuticals, Inc.
    Inventors: Graham P. Allaway, Virginia M. Litwin, Paul J. Maddon, William C. Olson
  • Patent number: 6312939
    Abstract: DNA encoding a therapeutically suitable glutaminase has been molecularly cloned. This allows one to obtain a polypeptide which is a therapeutically suitable glutaminase free of contaminating endotoxin. It has been found that this polypeptide is a potent anti-viral agent and when coupled to an anti-tumor monoclonal antibody is a potent anti-cancer agent. The glutaminase of the present invention is particularly useful for treating lung, breast and colon cancer cells and in the treatment of HIV-infected cells.
    Type: Grant
    Filed: April 25, 1995
    Date of Patent: November 6, 2001
    Assignee: ME Medical Enzymes AG
    Inventors: Joseph Roberts, Thomas W MacAllister, Natarajan Sethuraman, Abbie G. Freeman
  • Patent number: 6303299
    Abstract: The invention relates to a method for studying translation initiation and for identifying potential inhibitors of translation initiation by expressing proteins in the presence of misacylated suppressor tRNAs.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: October 16, 2001
    Assignee: University of Virginia Patent Foundation
    Inventors: Sidney M. Hecht, Vladimir Karginov, Andrei V. Karginov
  • Patent number: 6284240
    Abstract: Disclosed is a method of directing a cellular immune response against an HIV-infected cell in a mammal involving administering to the mammal an effective amount of therapeutic cells which express a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell. Also disclosed are cells which express the chimeric receptors and DNA and vectors encoding the chimeric receptors.
    Type: Grant
    Filed: December 22, 1998
    Date of Patent: September 4, 2001
    Assignee: The General Hospital Corporation
    Inventors: Brian Seed, Babak Banapour, Charles Romeo, Waldemar Kolanus
  • Patent number: 6277586
    Abstract: The invention provides cDNA molecules comprising a part of the cDNA sequence of GAD65 which encode at least one epitope for autoantibodies to GAD65. The invention also provides cloning vehicles capable of replication and expression comprising cDNA molecules coding for GAD65. The invention further provides for hosts transformed with a vehicle having a cDNA molecule coding for GAD65. In another embodiment, the invention provides for the detection of autoantibodies to GAD65 using the GAD65 polypeptides coded for by the cDNA molecules of the invention.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: August 21, 2001
    Assignee: Regents of the University of California
    Inventors: Allan J. Tobin, Mark G. Erlander, Daniel L. Kaufman
  • Patent number: 6265160
    Abstract: Agents which inhibit the Jak-Stat signal transduction pathway are identified in order to identify candidate drugs for treatment of proliferative disorders. Identification methods are alternatively based on inhibiting the interaction of: (1) the activated Stat3 and Stat5 transcription factors with an electrophoretic mobility shift assay probe, or (2) the Stat3 or Stat5 proteins with the IL-2R&bgr; chain of the IL-2 receptor.
    Type: Grant
    Filed: January 7, 1998
    Date of Patent: July 24, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventor: Warren J. Leonard
  • Patent number: 6258527
    Abstract: Entry of HIV-1 into target cells requires cell surface CD4 as well as additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T cell lines was recently identified and named fusin. Fusin, however, does not promote entry of macrophage-tropic viruses that are believed to be the key pathogenic strains in vivo. It has now been determined that the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR5, a receptor for the &bgr;-chemokines RANTES, MIP-1&agr;, and MIP-1&bgr;.
    Type: Grant
    Filed: May 21, 1997
    Date of Patent: July 10, 2001
    Assignees: The Aaron Diamond Aids Research Center, New York University
    Inventors: Dan R. Littman, Hongkui Deng, Wilfried Ellmeier, Nathaniel R. Landau, Rong Liu
  • Patent number: 6241986
    Abstract: Human monoclonal antibodies specific for the CD4-binding domain of HIV gp120 are useful in the neutralization of HIV and in the prevention of HIV infection and the treatment of a subject infected with HIV. Such antibodies and heterohybridomas producing them are disclosed. Synergistic mixtures of at least two human monoclonal antibodies specific for two different epitopes of gp120 are used to neutralize HIV, to prevent HIV infection and to treat a subject infected with HIV. In this synergistic mixture, one antibody has broad HIV group specificity, and is preferably specific for the CD4-binding domain. The other antibody is preferably specific for the V3 loop and has a range of neutralizing activity such that it neutralizes virus of the MN strain, MN-like families, and widely divergent HIV-1 isolates which are members of various V3 lop classes.
    Type: Grant
    Filed: March 21, 1994
    Date of Patent: June 5, 2001
    Assignee: New York University
    Inventors: Susan Zolla-Pazner, Miroslaw K. Gorny, Sylwia Karwowska, Aby Buchbinder
  • Patent number: 6218181
    Abstract: The present invention provides packaging cell lines and recombinant lentiviral or retroviral particles produced therefrom, particularly pseudotyped retroviral particles. The packaging cell lines of the invention are produced by inducibly expressing an envelope protein by methods described herein. Also described is a screening assay for compounds that affect integration of viral nucleic acid into target (e.g., host) nucleic acid. Such compounds are identified based on their effect on viral integrase.
    Type: Grant
    Filed: September 3, 1998
    Date of Patent: April 17, 2001
    Assignee: The Salk Institute for Biological Studies
    Inventors: Inder M. Verma, Tal Kafri, Frederic Bushman, Mark Hansen
  • Patent number: 6218102
    Abstract: There is provided cyclic peptides of the general formula where x represents any amino acid sequence or analogues located from amino acid 586 to amino acid 602 gp4l (HIV-1) y represents any amino acid sequence or analogues located from amino acid 611 to amino acid 620 gp4l (HIV-1); and a and b represent the amino and carboxy terminals, respectively, as well as substituents which are effective to make the peptides more useful as an immunodiagnostic reagent. These cyclic peptides alone or in admixture with certain linear peptides are particularly useful in detecting HIV antibodies.
    Type: Grant
    Filed: January 27, 1988
    Date of Patent: April 17, 2001
    Assignee: Biochem Immunosystems, Inc.
    Inventors: Francesco Bellini, Gervais Dionne, Martial Lacroix
  • Patent number: 6214537
    Abstract: There is provided cyclic peptides of the general formula wherein x represents the amino terminus, one amino acid or amino acid sequence starting with amino add 604 and going back as far as amino acid 586 (gp41-HIV-1); and y represents the carboxy terminus, an amino acid or amino acid sequence starting with amino acid 612 and extending up to amino acid 629 (gp41-HIV-1). There is also provided peptides of the general formula wherein x1 represents the amino terminus, one amino acid or amino acid sequence starting with amino add 596 and going back as far as amino acid 578 (gp42-HIV-2) and a and b represent the amino and carboxy terminals, respectively, as well as substituents which are effective to make the peptides more useful as an immunodiagnostic reagent; and y1 represents the carboxy terminus, an amino acid or amino add sequence starting with amino acid 604 and extending up to amino acid 613 (gp42-HIV-2) and a and b are as defined previously.
    Type: Grant
    Filed: December 8, 1988
    Date of Patent: April 10, 2001
    Assignee: Biochem Immunosystems, Inc.
    Inventors: Francesco Bellini, Gervais Dionne, Martial Lacroix
  • Patent number: 6210874
    Abstract: Cyclic peptides of the general formulae: wherein x represents an amino acid sequence from position 585 to 604 (gp41-HIV-1) with at least one of a lysine at position 586 or a lysine at both positions 585 and 586; x2 represents an amino acid sequence from position 585 to 604 (gp41-HIV-1); y represents an amino acid sequence from position 612 to 629 (gp41-HIV-1); e and f represent one or more epitopes included in the amino acid sequence extending from 586 to 629 (gp41-HIV-1) or from 578 to 613 (gp36-HIV-2); and a and b represent the amino and carboxy terminals, respectively, as well as substituents effective to make the peptide more useful as an immunodiagnostic. Peptides of formula III have one or both of e and f present.
    Type: Grant
    Filed: May 1, 1995
    Date of Patent: April 3, 2001
    Assignee: Biochem Immunosystems, Inc.
    Inventor: Martial Lacroix
  • Patent number: 6197531
    Abstract: A method for determining the immunocompetence of a mammal is described. Bodily fluid having T cell receptor complexes from a mammal is provided. Expression of a first component and a second component of the T cell receptor complexes is evaluated. An abnormal ratio of the number of cells expressing the first component as compared to the number of cells expressing the second component indicates altered immunocompetence in the mammal.
    Type: Grant
    Filed: January 21, 1998
    Date of Patent: March 6, 2001
    Assignee: Center For Blood Research, Inc.
    Inventor: Judy Lieberman
  • Patent number: 6156541
    Abstract: A catalytic antibody and components thereof which cleave HIV gp120 are disclosed. Methods of isolating, cloning and purifying such antibodies or antibody components from patients are also described. The compositions described may provide utility in the treatment of HIV infection.
    Type: Grant
    Filed: January 21, 1998
    Date of Patent: December 5, 2000
    Assignee: The Board of Regents of the University of Nebraska
    Inventors: Sudhir Paul, Ravishankar Kalaga
  • Patent number: 6153431
    Abstract: The present invention relates to variants of the CCR5 human immunodeficiency virus ("HIV") co-receptor which result in a resistance of CCR5 expressing cells to HIV infection. The detection of such mutations may be used to identify individuals at lower risk for infection relative to the general population who, if infected, may exhibit slower progression to AIDS. Further, the present invention provides for methods of inhibiting HIV infection of a cell expressing the CCR5 receptor, comprising introducing, into the cell, a nucleic acid encoding a CCR5 variant.
    Type: Grant
    Filed: May 28, 1998
    Date of Patent: November 28, 2000
    Inventors: Alberto Beretta, Caroline Quillent, Fernando Arenzana Siesdedos, Josephine Braun
  • Patent number: 6136321
    Abstract: The invention relates to a method of inactivating lipid-enveloped viruses by means of a non-ionic detergent, and the preparation of a vaccine containing the inactivated virus. The invention further relates to an inactivated virus which is characterized by its structural integrity, in particular the structural integrity of its enveloping proteins, as well as to the use of the inactivated virus for preparing a vaccine.
    Type: Grant
    Filed: February 10, 1998
    Date of Patent: October 24, 2000
    Assignee: Baxter Aktiengesellschaft
    Inventors: Noel Barrett, Otfried Kistner, Friedrich Dorner